233 related articles for article (PubMed ID: 30598193)
1. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease.
Verzola D; Barisione C; Picciotto D; Garibotto G; Koppe L
Kidney Int; 2019 Mar; 95(3):506-517. PubMed ID: 30598193
[TBL] [Abstract][Full Text] [Related]
2. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Han HQ; Zhou X; Mitch WE; Goldberg AL
Int J Biochem Cell Biol; 2013 Oct; 45(10):2333-47. PubMed ID: 23721881
[TBL] [Abstract][Full Text] [Related]
3. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of myostatin and activin A accumulation in chronic kidney disease.
Bataille S; Dou L; Bartoli M; Sallée M; Aniort J; Ferkak B; Chermiti R; McKay N; Da Silva N; Burtey S; Poitevin S
Nephrol Dial Transplant; 2022 Jun; 37(7):1249-1260. PubMed ID: 35333341
[TBL] [Abstract][Full Text] [Related]
5. Myostatin and muscle atrophy during chronic kidney disease.
Bataille S; Chauveau P; Fouque D; Aparicio M; Koppe L
Nephrol Dial Transplant; 2021 Nov; 36(11):1986-1993. PubMed ID: 32974666
[TBL] [Abstract][Full Text] [Related]
6. Myostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification.
Esposito P; Verzola D; Picciotto D; Cipriani L; Viazzi F; Garibotto G
Cells; 2021 Aug; 10(8):. PubMed ID: 34440838
[TBL] [Abstract][Full Text] [Related]
7. IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.
Liu D; Qiao X; Ge Z; Shang Y; Li Y; Wang W; Chen M; Si S; Chen SZ
Skelet Muscle; 2019 Mar; 9(1):8. PubMed ID: 30922397
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy.
Samant SA; Kanwal A; Pillai VB; Bao R; Gupta MP
Sci Rep; 2017 Sep; 7(1):11877. PubMed ID: 28928419
[TBL] [Abstract][Full Text] [Related]
9. Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A.
Lee SJ; Lehar A; Liu Y; Ly CH; Pham QM; Michaud M; Rydzik R; Youngstrom DW; Shen MM; Kaartinen V; Germain-Lee EL; Rando TA
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):30907-30917. PubMed ID: 33219121
[TBL] [Abstract][Full Text] [Related]
10. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
11. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
Solagna F; Tezze C; Lindenmeyer MT; Lu S; Wu G; Liu S; Zhao Y; Mitchell R; Meyer C; Omairi S; Kilic T; Paolini A; Ritvos O; Pasternack A; Matsakas A; Kylies D; Wiesch JSZ; Turner JE; Wanner N; Nair V; Eichinger F; Menon R; Martin IV; Klinkhammer BM; Hoxha E; Cohen CD; Tharaux PL; Boor P; Ostendorf T; Kretzler M; Sandri M; Kretz O; Puelles VG; Patel K; Huber TB
J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 34060483
[TBL] [Abstract][Full Text] [Related]
12. Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight.
Lee SJ; Lehar A; Meir JU; Koch C; Morgan A; Warren LE; Rydzik R; Youngstrom DW; Chandok H; George J; Gogain J; Michaud M; Stoklasek TA; Liu Y; Germain-Lee EL
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23942-23951. PubMed ID: 32900939
[TBL] [Abstract][Full Text] [Related]
13. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.
Lach-Trifilieff E; Minetti GC; Sheppard K; Ibebunjo C; Feige JN; Hartmann S; Brachat S; Rivet H; Koelbing C; Morvan F; Hatakeyama S; Glass DJ
Mol Cell Biol; 2014 Feb; 34(4):606-18. PubMed ID: 24298022
[TBL] [Abstract][Full Text] [Related]
14. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling.
Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493
[TBL] [Abstract][Full Text] [Related]
15. Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation.
Wang Q; McPherron AC
J Physiol; 2012 May; 590(9):2151-65. PubMed ID: 22393251
[TBL] [Abstract][Full Text] [Related]
16. [Role of Activin A and Myostatin in cancer cachexia].
Thissen JP; Loumaye A
Ann Endocrinol (Paris); 2013 May; 74(2):79-81. PubMed ID: 23566617
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions.
Watanabe H; Enoki Y; Maruyama T
Biol Pharm Bull; 2019; 42(9):1437-1445. PubMed ID: 31474705
[TBL] [Abstract][Full Text] [Related]
19. Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease.
Yu R; Chen JA; Xu J; Cao J; Wang Y; Thomas SS; Hu Z
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):327-341. PubMed ID: 27897418
[TBL] [Abstract][Full Text] [Related]
20. Computational Identification of Dithymoquinone as a Potential Inhibitor of Myostatin and Regulator of Muscle Mass.
Ahmad SS; Ahmad K; Lee EJ; Shaikh S; Choi I
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
